Transatlantic Gamble: Scancell's $25M BlackRock Debt and the Race to Phase 3

OXFORD, United Kingdom – September 24, 2026 — In the biotechnology sector, innovation frequently dies not in the laboratory, but on the balance sheet. For companies transitioning from promising mid-stage clinical data to the grueling reality of global Phase 3 trials, the cost of execution is astronomical. Today's announcement from Scancell Holdings plc that it has secured a debt facility of up to $25 million from funds managed by BlackRock is a textbook example of the complex financial engineering required to keep late-stage pipelines alive.

The debt package, provided by BlackRock affiliate Kreos Capital, is not an isolated transaction. It is the linchpin of an ambitious $89 million recapitalization strategy designed to fund the company's lead melanoma immunotherapy, iSCIB1+, through a pivotal Phase 3 trial. More importantly, it serves as the financial bridge for a transatlantic leap: an all-stock reverse merger with the Nasdaq-listed shell company Neuphoria Therapeutics Inc., intended to rescue Scancell from the valuation doldrums of London's AIM exchange.

Dr. Phil L’Huillier, CEO of Scancell, framed the maneuver strictly in terms of operational velocity. “The debt facility is an important part of an equity and debt package in conjunction with the planned merger that allows Scancell to proceed at pace to initiate and execute the global registrational Phase 3 trial for its lead programme, iSCIB1+,” he stated today.

The True Cost of Transatlantic Capital

For leaders who value execution over hype, the structure of the BlackRock debt facility warrants rigorous scrutiny. Venture debt of this magnitude in the biotech space is rarely cheap, and Scancell is paying a premium for liquidity.

The $25 million facility is structured across four tranches, designed to unlock only as Scancell de-risks its corporate and clinical milestones. An initial $7 million drawdown is strictly conditional upon shareholder approval at an Extraordinary General Meeting (EGM) scheduled for October 2026. A subsequent $8 million across two tranches will only become available once the Neuphoria US listing is complete and the first global Phase 3 clinical site for iSCIB1+ is officially operational. The final $10 million tranche remains available through the end of 2027, contingent upon minimum equity fundraising thresholds.

The cost of this capital reflects the inherent risks of late-stage drug development. The term loan carries a 10.50% annual interest rate payable monthly in cash, while the convertible portion bears a 10.95% rate capitalized into the principal. Furthermore, BlackRock retains the option to convert up to $5 million of the principal into ordinary shares at a 30% premium to Scancell's July 2026 fundraising price. Dilution is further guaranteed by warrant coverage equal to 4.5% of the drawn amounts.

Critically, the loan is secured against substantially all assets of the company, including the intellectual property underpinning its proprietary ImmunoBody and Moditope platforms. If clinical enrollment stalls or the Nasdaq listing fails to provide the expected liquidity, the standard 18-month interest-only period will quickly give way to aggressive amortization, placing immense pressure on the company's balance sheet right as it approaches its crucial data readouts.

Off-the-Shelf Execution vs. Personalized Hype

To understand why Scancell is willing to accept such stringent covenants, one must look at the quantifiable clinical potential of iSCIB1+. In an oncology market currently captivated by the rhetoric surrounding personalized mRNA neoantigen vaccines—such as the Moderna and Merck collaboration—Scancell is taking a decidedly more practical approach to advanced melanoma.

Personalized mRNA therapies require surgical biopsies, complex sequencing, and individual batch manufacturing that can take up to six weeks. They are currently being evaluated primarily in the adjuvant setting for early-stage disease. In contrast, iSCIB1+ is an off-the-shelf DNA plasmid vaccine delivered via a needle-free intramuscular injection. It utilizes the PharmaJet Stratis system, which eliminates needle-stick biohazards and mechanically drives enhanced intracellular plasmid uptake. By encoding melanoma-associated antigens gp100 and TRP-2 alongside additional HLA epitopes, the second-generation therapy is designed to treat approximately 80% of metastatic melanoma patients immediately upon diagnosis.

The clinical execution to date has been highly compelling. In the completed multi-center Phase 2 SCOPE trial, iSCIB1+ was administered alongside the standard-of-care doublet checkpoint inhibitors, nivolumab and ipilimumab, in previously untreated, unresectable Stage IIIB–IV melanoma. The data delivered a progression-free survival (PFS) rate of 77% at 22 months, with an overall survival rate of 87.4% at 18 months. When benchmarked against the historical median PFS of just 11.5 months for the checkpoint inhibitors alone, Scancell's therapy represents a massive, quantifiable leap in efficacy without introducing compounded autoimmune toxicities.

This robust Phase 2 foundation is what convinced the FDA to grant Fast Track Designation and clear the Investigational New Drug (IND) application in January 2026. The upcoming 550-patient randomized Phase 3 trial is designed with a streamlined regulatory pathway, targeting accelerated FDA approval based on interim PFS data expected in the second half of 2028.

Engineering Shareholder Consent

Executing this clinical vision requires navigating a complex web of shareholder dynamics ahead of the October EGM. UK retail investors have historically been hostile to US reverse mergers, particularly when accompanied by discounted equity placements. To mitigate friction over the 9.0p placement price—a steep discount prior to the July announcement—Scancell smartly initiated a $3 million UK retail offer, providing existing smaller shareholders pro-rata access to the institutional terms.

However, the ultimate success of the EGM vote is largely secured by Scancell's cornerstone institutional backers. Redmile Group, the company's largest shareholder, has agreed to convert over $24 million in existing convertible loan notes into restricted American Depositary Shares (ADSs) and non-voting ordinary shares, carefully managing its voting stake to comply with the UK Takeover Code. Both Redmile and long-time backer Vulpes Investment Management have entered into binding support deeds, virtually guaranteeing the approval of the BlackRock facility and the Neuphoria merger.

As Scancell prepares to transition its primary financial center of gravity from Oxford to Massachusetts, the company has successfully assembled the capital required to move from promising pilot data to full-scale clinical production. The BlackRock debt facility is expensive, and the covenants are unforgiving, but in the brutal calculus of biotech development, owning the capital to cross the finish line is the only metric that matters. The financial scaffolding is now in place; the burden of proof shifts entirely to the Phase 3 clinical execution.